Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma
PurposeIn patients with resectable esophageal squamous cell carcinoma (ESCC), neoadjuvant therapy increased the curative resection rate, disease-free survival, and overall survival for patients with resectable ESCC. However, the efficacy of neoadjuvant therapy varies among different patients. We aim...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1320282/full |
| _version_ | 1797384266723622912 |
|---|---|
| author | Xin Nie Shuya He Xinming Nie Changding Li Kunyi Du Wenwu He Zhiyu Li Kunhan Ni Simiao Lu Chenghao Wang Kangning Wang Yan Miao Longlin Jiang Jiahua Lv Guangyuan Liu Qiang Fang Lin Peng Wenguang Xiao Qifeng Wang Dongsheng Wang Yongtao Han Xuefeng Leng |
| author_facet | Xin Nie Shuya He Xinming Nie Changding Li Kunyi Du Wenwu He Zhiyu Li Kunhan Ni Simiao Lu Chenghao Wang Kangning Wang Yan Miao Longlin Jiang Jiahua Lv Guangyuan Liu Qiang Fang Lin Peng Wenguang Xiao Qifeng Wang Dongsheng Wang Yongtao Han Xuefeng Leng |
| author_sort | Xin Nie |
| collection | DOAJ |
| description | PurposeIn patients with resectable esophageal squamous cell carcinoma (ESCC), neoadjuvant therapy increased the curative resection rate, disease-free survival, and overall survival for patients with resectable ESCC. However, the efficacy of neoadjuvant therapy varies among different patients. We aim to compare the differences in the characteristics of peripheral blood T lymphocyte subsets before and after neoadjuvant therapy in patients with different curative efficacy.MethodThis study enrolled 266 ESCC patients who received neoadjuvant therapy and esophagectomy from August 2018 to August 2022. The postoperative pathological results divided patients into the major pathological response (MPR) and non-MPR groups. Compare the differences in peripheral blood T lymphocyte subsets and analyze the trend of changes in T lymphocyte subsets at different phases of treatment. Propensity score matching was used to reduce the influence of potential confounding factors.ResultsPrior to the neoadjuvant therapy, particularly before the second cycle, the MPR group exhibited significantly higher ratios of CD4/CD8 (P=0.009) and helper T cells (TH ratio, P=0.030) compared to the non-MPR group. In contrast, the suppressor T cell ratio (TS ratio) was lower (P=0.016) in the MPR group. The difference in peripheral blood lymphocyte subsets between the two groups of patients who underwent neoadjuvant chemoradiotherapy is significant.ConclusionIn peripheral blood, T lymphocyte subsets varied significantly based on the effectiveness of neoadjuvant treatment. Prior to the second cycle of neoadjuvant therapy, a higher CD4/CD8 and TH ratio, coupled with a decreased TS ratio, might suggest enhanced treatment outcomes. |
| first_indexed | 2024-03-08T21:32:59Z |
| format | Article |
| id | doaj.art-3a60103fe95b43be8b5bc20d0bfc4c35 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T21:32:59Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3a60103fe95b43be8b5bc20d0bfc4c352023-12-21T04:38:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-12-011410.3389/fimmu.2023.13202821320282Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinomaXin Nie0Shuya He1Xinming Nie2Changding Li3Kunyi Du4Wenwu He5Zhiyu Li6Kunhan Ni7Simiao Lu8Chenghao Wang9Kangning Wang10Yan Miao11Longlin Jiang12Jiahua Lv13Guangyuan Liu14Qiang Fang15Lin Peng16Wenguang Xiao17Qifeng Wang18Dongsheng Wang19Yongtao Han20Xuefeng Leng21Department of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Clinical Laboratory, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Clinical Laboratory, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, ChinaPurposeIn patients with resectable esophageal squamous cell carcinoma (ESCC), neoadjuvant therapy increased the curative resection rate, disease-free survival, and overall survival for patients with resectable ESCC. However, the efficacy of neoadjuvant therapy varies among different patients. We aim to compare the differences in the characteristics of peripheral blood T lymphocyte subsets before and after neoadjuvant therapy in patients with different curative efficacy.MethodThis study enrolled 266 ESCC patients who received neoadjuvant therapy and esophagectomy from August 2018 to August 2022. The postoperative pathological results divided patients into the major pathological response (MPR) and non-MPR groups. Compare the differences in peripheral blood T lymphocyte subsets and analyze the trend of changes in T lymphocyte subsets at different phases of treatment. Propensity score matching was used to reduce the influence of potential confounding factors.ResultsPrior to the neoadjuvant therapy, particularly before the second cycle, the MPR group exhibited significantly higher ratios of CD4/CD8 (P=0.009) and helper T cells (TH ratio, P=0.030) compared to the non-MPR group. In contrast, the suppressor T cell ratio (TS ratio) was lower (P=0.016) in the MPR group. The difference in peripheral blood lymphocyte subsets between the two groups of patients who underwent neoadjuvant chemoradiotherapy is significant.ConclusionIn peripheral blood, T lymphocyte subsets varied significantly based on the effectiveness of neoadjuvant treatment. Prior to the second cycle of neoadjuvant therapy, a higher CD4/CD8 and TH ratio, coupled with a decreased TS ratio, might suggest enhanced treatment outcomes.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1320282/fullesophageal squamous cell carcinomaneoadjuvant chemoradiotherapylymphocyte subsetsperipheral blood cellmajor pathological response |
| spellingShingle | Xin Nie Shuya He Xinming Nie Changding Li Kunyi Du Wenwu He Zhiyu Li Kunhan Ni Simiao Lu Chenghao Wang Kangning Wang Yan Miao Longlin Jiang Jiahua Lv Guangyuan Liu Qiang Fang Lin Peng Wenguang Xiao Qifeng Wang Dongsheng Wang Yongtao Han Xuefeng Leng Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma Frontiers in Immunology esophageal squamous cell carcinoma neoadjuvant chemoradiotherapy lymphocyte subsets peripheral blood cell major pathological response |
| title | Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma |
| title_full | Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma |
| title_fullStr | Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma |
| title_full_unstemmed | Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma |
| title_short | Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma |
| title_sort | peripheral t lymphocyte and immunocyte subset dynamics markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma |
| topic | esophageal squamous cell carcinoma neoadjuvant chemoradiotherapy lymphocyte subsets peripheral blood cell major pathological response |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1320282/full |
| work_keys_str_mv | AT xinnie peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT shuyahe peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT xinmingnie peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT changdingli peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT kunyidu peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT wenwuhe peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT zhiyuli peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT kunhanni peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT simiaolu peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT chenghaowang peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT kangningwang peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT yanmiao peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT longlinjiang peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT jiahualv peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT guangyuanliu peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT qiangfang peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT linpeng peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT wenguangxiao peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT qifengwang peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT dongshengwang peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT yongtaohan peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma AT xuefengleng peripheraltlymphocyteandimmunocytesubsetdynamicsmarkersofneoadjuvanttherapyoutcomesinesophagealsquamouscellcarcinoma |